Table 5.

Sensitivity of multivariate risk stratification from CA125, ROMA and MIA2G by primary histology—all evaluable subjects

	CA125	ROMA	MIA2G
Epithelial, %	83.3	89.3	96.7
n/N	125/150	134/150	145/150
95% CI	76.6–88.4	83.4–93.3	92.4–98.6
Non-epithelial, %	37.5	56.3	75.0
n/N	6/16	9/16	12/16
95% CI	18.5–61.4	33.2–76.9	50.5–89.8
LMP, %	42.9	50.0	76.2
n/N	18/42	21/42	32/42
95% CI	29.1–57.8	35.5–64.5	61.5–86.5
Metastatic, %	78.3	87.0	95.7
n/N	18/23	20/23	22/23
95% CI	58.1–90.3	67.9–95.5	79.0–99.2
Non-ovarian,  %	50.0	71.4	85.7
n/N	7/14	10/14	12/14
95% CI	26.8–73.2	45.4–88.3	60.1–96.0

CA125 high-risk cutoff: premenopausal subjects > 200 U/ml, postmenopausal subjects > 35 U/ml; ROMA high-risk cutoff: premenopausal subjects ≥ 11.4, postmenopausal subjects ≥ 29.9